Results 151 to 160 of about 85,259 (288)

PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Upifitamab rilsodotin—an antibody drug conjugate (ADC)—comprises a NaPi2b‐targeted antibody conjugated to an auristatin‐based payload (auristatin F‐hydroxypropylamide [AF‐HPA]). AF‐HPA is metabolized by cytochrome P450 3A4 (CYP3A4) and, to a lower extent, by CYP3A5 and demonstrates both reversible and time‐dependent inhibition of CYP3A4.
Niyanta Kumar, Vaishali Dixit, Howard Burt, Katherine L. Gill, Hannah M. Jones, Natalie Keirstead, Dian Su, Dorin Toader, Timothy B. Lowinger   +8 more
wiley   +1 more source

Performance Evaluation of a HBsAg-Specific Immunoadsorbent Based on a Humanized Anti-HBsAg Monoclonal Antibody. [PDF]

Biomedicines
Gao S, Cai X, Yan T, Wang Y, Tao X.
europepmc   +1 more source

Criteria for Dose Adjustment of Tildrakizumab in Psoriasis Vulgaris

JEADV Clinical Practice, EarlyView.
Andreas Pinter, Diamant Thaçi, Michael Sebastian   +2 more
wiley   +1 more source

Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in chronic spontaneous urticaria (CSU) illustrated how MIDD can be applied to support central aspects of
Andrzej Bienczak, Aurelie Gautier, Eva Hua, Yan Ji, Emil Scosyrev, Serge Smeets, Thomas Severin, Anton Drollmann, Manmath Patekar, Marina Savelieva   +9 more
wiley   +1 more source

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus. [PDF]

BMC Biotechnol
Zhang Z, Li J, Lin G, Cao S, Wu Y.
europepmc   +1 more source

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)‐directed antibody‐drug conjugate (ADC) developed for the treatment of advanced or metastatic solid tumors. Dato‐DXd demonstrated promising antitumor activity and a manageable safety profile in the first‐in‐human Phase 1 study TROPION‐PanTumor01.
Ying Hong, Sophie Peigné, Υuzhuo Pan, Sofia Friberg Hietala, Anna McLaughlin, Naoyuki Tajima, Deise Uema, Hong Zebger‐Gong, Zoey Tang, Diansong Zhou, Malaz Abutarif, Τushar Garimella   +11 more
wiley   +1 more source

<i>In vitro</i> and <i>in vivo</i> evaluation of humanized monoclonal antibodies targeting pneumolysin. [PDF]

Microbiol Spectr
Song L, Hu H, Huang J, Li H, Zhang Y, Ma N, Song Z.   +6 more
europepmc   +1 more source

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

VIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li, Yukun Li, Yao Li, Mingqi Yang, Haichuan Peng, Hongwei Sun, Ping Jiang, Yizhun Zhu, Qiang Chen, Xiaobing Duan, Wei Zhao   +10 more
wiley   +1 more source

Health Technology Assessment: Evaluation of Monoclonal Antibodies for the Treatment of Neuromyelitis Optica Spectrum Disorders. [PDF]

Drug Des Devel Ther
Wang C, Wu H, Huang Y, Liu A, Lai S.
europepmc   +1 more source

Current Insights Into Individualized Diagnosis and Treatment of Allergic Rhinitis Based on Phenotype and Endotype

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu, Long‐Lan Shu, Tao Lu, Da‐Yu Guan, Bo‐Wen Zheng, Pan‐Hui Xiong, Yang Shen, Yu‐Cheng Yang   +7 more
wiley   +1 more source